

1. I am analysing the usage of intra-vitreous injections or implants by the NHS. Could you please tell me how many of the following intra-vitreous injections/implants has your trust administered in the four-month period from September to December 2022:

Aflibercept

- **Bevacizumab**
- **Brolucizumab**
- **Dexamethasone**
- **Faricimab**
- **Ranibizumab - Lucentis**
- **Ranibizumab – Ongavia**

The Health Board is unable to provide information on the number of intra-vitreous injections or implants, however, please find below the quantities dispensed, across Health Board pharmacies for 'any disease' for the period September 2022 – December 2022:

Drug	Quantity
AFLIBERCEPT (EYLEA) 3.6 mg in 0.09mL Pre-Filled Syringe 1 Pre-Filled Syringe Pack	4249
BEVACIZUMAB 1.25 mg in 0.05mL Pre-Filled Syringe 1 Pre-Filled Syringe Pack	1
DEXAMETHASONE 700 micrograms Implant 1 Implant Pack	5
FARICIMAB 28.8 mg in 0.24mL Intravitreal Injection 1 Vial Pack	5
RANIBIZUMAB (LUCENTIS) 1.65 mg in 0.165mL Pre-Filled Syringe 1 Pre-Filled Syringe Pack	909
RANIBIZUMAB (ONGAVIA) 2.3 mg in 0.23mL Intravitreal Injection 1 Vial Pack	80

